The study and its comparison
A multicenter blinded study randomized 1,741 people with early, treated Parkinson’s disease to creatine monohydrate or placebo. The planned five-year comparison combined several measures of function and clinical status. [1]
The trial stopped after a planned interim analysis showed futility. Median follow-up was four years; the interim five-year cohort included 955 participants. The combined clinical comparison did not favor creatine. [1]
What the finding establishes
Planned duration should not be confused with follow-up achieved by every participant. The result concerns disease progression and does not negate separate exercise research. NINDS organized the program, and authors disclosed numerous consulting relationships; complete funding was not established from the abstract. The study does not support using creatine as a disease-modifying Parkinson treatment. [1]
A hypothetical distinction
Imagine a five-year trial stops early with median follow-up of four years. Report both the plan and the achieved observation.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.